BiostaxRx
A wholly owned telehealth and inflammaging subsidiary set to launch in Q4 '23 / Q1 '24
BiostaxRx was founded on the principle that effective and affordable treatments now exist that address a large variety of chronic inflammatory diseases; and those that safely reduce inflammation without suppressing the immune system will take center stage in delivering a high quality of life to the greatest number of patients.
Telehealth Platform
Our internal team is currently working on the development of innovative telehealth, EHR and revenue platforms seeking to integrate blockchain. We hope to deliver on several opportunities that include typical telemedicine infrastructures and blockchain secured solutions such as patient consent management, traceability of remote treatments and in-home medical kits, secure access to EHRs, improved secure prescription services and more.
Exclusive Compounders
Biostax is currently in discussions with a national network of 503A/B compounding pharmacies that will provide innovative and quality inflammaging therapies
Diverse Pipeline
BiostaxRx is preparing to deliver a host of therapies, including compounded LDN, botanicals focused on inflammatory disorders and nutraceuticals. Utilizing the technologies developed by Biostax, we hope to develop DTC (direct to consumer) channels for future Biostax approved products.
Pipeline Growth
Pipeline intends to expand to include exclusive bone health supplements, a complete CBD line, neuroinflammation botanicals and BHRT
